Rapid Review Quiz: New Diagnostic Tests

Elwyn C. Cabebe, MD; Herbert S. Diamond, MD; Michael Stuart Bronze, MD; Helmi L. Lutsep, MD

Disclosures

June 13, 2022

In the study, Larkin and colleagues tested whether biomarkers within the blood metabolome could detect cancers within a mixed population of patients referred from primary care with nonspecific symptoms. The researchers reported that an NMR-based metabolomic analysis correctly detected solid tumors and identified metastatic disease (including breast cancer) among patients with a 94% rate of accuracy.

Furthermore, the NMR-based technique analyzed levels of metabolites in the blood as biomarkers to distinguish different cancer states using magnetic fields and radio waves. Larkin and colleagues emphasized a need to confirm the results in a larger cohort of patients and evaluate the test's use in a wider clinical context.

Learn more about the presentation of metastatic breast cancer.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....